Literature DB >> 20101737

Adult acute lymphoblastic leukemia: concepts and strategies.

Stefan Faderl1, Susan O'Brien, Ching-Hon Pui, Wendy Stock, Meir Wetzler, Dieter Hoelzer, Hagop M Kantarjian.   

Abstract

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010. (c) 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20101737      PMCID: PMC5345568          DOI: 10.1002/cncr.24862

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  87 in total

1.  Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors:  Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

2.  A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.

Authors:  Marco Mancini; Daniela Scappaticci; Giuseppe Cimino; Mauro Nanni; Valentina Derme; Loredana Elia; Agostino Tafuri; Marco Vignetti; Antonella Vitale; Antonio Cuneo; Gianluigi Castoldi; Giuseppe Saglio; Fabrizio Pane; Cristina Mecucci; Andrea Camera; Giorgina Specchia; Alessandra Tedeschi; Francesco Di Raimondo; Giuseppe Fioritoni; Francesco Fabbiano; Filippo Marmont; Felicetto Ferrara; Nicola Cascavilla; Giuseppe Todeschini; Francesco Nobile; Maria Grazia Kropp; Pietro Leoni; Antonio Tabilio; Mario Luppi; Luciana Annino; Franco Mandelli; Robin Foà
Journal:  Blood       Date:  2005-01-13       Impact factor: 22.113

3.  Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

Authors:  Dan Douer; Henry Yampolsky; Lewis J Cohen; Kristy Watkins; Alexandra M Levine; Antonia P Periclou; Vassilios I Avramis
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.

Authors:  V M Belkov; E Y Krynetski; J D Schuetz; Y Yanishevski; E Masson; S Mathew; S Raimondi; C H Pui; M V Relling; W E Evans
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 5.  Transplants in Adult ALL--? Allo for everyone.

Authors:  Anthony H Goldstone
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

6.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Authors:  Xavier Thomas; Jean-Michel Boiron; Françoise Huguet; Hervé Dombret; Ken Bradstock; Norbert Vey; Tibor Kovacsovics; André Delannoy; Nathalie Fegueux; Pierre Fenaux; Aspasia Stamatoullas; Jean-Paul Vernant; Olivier Tournilhac; Agnès Buzyn; Oumedaly Reman; Christiane Charrin; Claude Boucheix; Jean Gabert; Véronique Lhéritier; Denis Fiere
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544

7.  Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.

Authors:  Orietta Spinelli; Barbara Peruta; Manuela Tosi; Vittoria Guerini; Anna Salvi; Maria Cristina Zanotti; Elena Oldani; Anna Grassi; Tamara Intermesoli; Caterina Micò; Giuseppe Rossi; Pietro Fabris; Giorgio Lambertenghi-Deliliers; Emanuele Angelucci; Tiziano Barbui; Renato Bassan; Alessandro Rambaldi
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

8.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors:  R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

Review 9.  DNA methylation as a therapeutic target in cancer.

Authors:  Jean-Pierre J Issa
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

Review 10.  The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.

Authors:  Dina Attias; Sheila Weitzman
Journal:  Curr Opin Pediatr       Date:  2008-02       Impact factor: 2.856

View more
  77 in total

1.  Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Tapan M Kadia; Hagop M Kantarjian; Deborah A Thomas; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Naveen Pemmaraju; Naval Daver; Xuemei Wang; Preetesh Jain; Sherry Pierce; Mark Brandt; Guillermo Garcia-Manero; Jorge Cortes; Gautam Borthakur
Journal:  Am J Hematol       Date:  2014-11-19       Impact factor: 10.047

Review 2.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

3.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

4.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

5.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

Review 6.  Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia.

Authors:  Prathap Jacob Joseph; Maria Regina Reyes
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

Review 7.  Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.

Authors:  Jacob S Appelbaum; Filippo Milano
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 8.  Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

Authors:  Naval Daver; Susan O'Brien
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

9.  Are incidence rates of adult leukemia in the United States significantly associated with birth cohort?

Authors:  Philip S Rosenberg; Katherine L Wilson; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-12       Impact factor: 4.254

10.  The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia.

Authors:  Dandan Lin; Chunliang Liu; Mengxing Xue; Rengyun Liu; Lan Jiang; Xiao Yu; Guangming Bao; Fang Deng; Mingjie Yu; Jiafu Ao; Yifeng Zhou; Depei Wu; Haiyan Liu
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.